Anthony M. Manning, a director at Monte Rosa Therapeutics (NASDAQ:GLUE), sold 10,000 shares of common stock on May 21, 2026, generating $180,100.
The shares were sold at $18.01 each. The sale follows a 366% surge in stock price over the past year.
Manning had acquired the shares through stock option exercises at $4.16 per share. He now holds no direct common stock but retains 12,100 options.
Analysts maintain price targets between $29 and $37. Bond.az analysis suggests the stock is currently overvalued.
In recent news, Monte Rosa reported positive Phase 1/2 results for MRT-2359 in prostate cancer, with a 100% PSA response rate. Preclinical data for MRT-55811 showed tumor regression in ovarian, breast, and gastric cancer models.
Guggenheim and Jefferies lowered price targets to $30 while maintaining Buy ratings. Three programs (NEK7, GSPT1, VAV1) are advancing to Phase 2 this year.
